These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1942 related items for PubMed ID: 32461349

  • 21. IL-15 can signal via IL-15Rα, JNK, and NF-κB to drive RANTES production by myeloid cells.
    Chenoweth MJ, Mian MF, Barra NG, Alain T, Sonenberg N, Bramson J, Lichty BD, Richards CD, Ma A, Ashkar AA.
    J Immunol; 2012 May 01; 188(9):4149-57. PubMed ID: 22447977
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy.
    Ohno Y, Toyoshima Y, Yurino H, Monma N, Xiang H, Sumida K, Kaneumi S, Terada S, Hashimoto S, Ikeo K, Homma S, Kawamura H, Takahashi N, Taketomi A, Kitamura H.
    Cancer Sci; 2017 Oct 01; 108(10):1959-1966. PubMed ID: 28746799
    [Abstract] [Full Text] [Related]

  • 24. CXCL9 and CXCL10 expression are critical for control of genital herpes simplex virus type 2 infection through mobilization of HSV-specific CTL and NK cells to the nervous system.
    Thapa M, Welner RS, Pelayo R, Carr DJ.
    J Immunol; 2008 Jan 15; 180(2):1098-106. PubMed ID: 18178850
    [Abstract] [Full Text] [Related]

  • 25. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy.
    Narvaiza I, Mazzolini G, Barajas M, Duarte M, Zaratiegui M, Qian C, Melero I, Prieto J.
    J Immunol; 2000 Mar 15; 164(6):3112-22. PubMed ID: 10706701
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans.
    Rowley J, Monie A, Hung CF, Wu TC.
    J Immunol; 2008 Dec 15; 181(12):8237-47. PubMed ID: 19050240
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy.
    Doorduijn EM, Sluijter M, Salvatori DC, Silvestri S, Maas S, Arens R, Ossendorp F, van der Burg SH, van Hall T.
    Cancer Immunol Res; 2017 Aug 15; 5(8):642-653. PubMed ID: 28637878
    [Abstract] [Full Text] [Related]

  • 30. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression.
    Gao HF, Cheng CS, Tang J, Li Y, Chen H, Meng ZQ, Chen Z, Chen LY.
    Aging (Albany NY); 2020 Jan 08; 12(1):502-517. PubMed ID: 31913856
    [Abstract] [Full Text] [Related]

  • 31. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.
    Bronger H, Kraeft S, Schwarz-Boeger U, Cerny C, Stöckel A, Avril S, Kiechle M, Schmitt M.
    Breast Cancer Res; 2012 Feb 14; 14(1):R30. PubMed ID: 22333315
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Targeted Delivery of CXCL9 and OX40L by Mesenchymal Stem Cells Elicits Potent Antitumor Immunity.
    Yin P, Gui L, Wang C, Yan J, Liu M, Ji L, Wang Y, Ma B, Gao WQ.
    Mol Ther; 2020 Dec 02; 28(12):2553-2563. PubMed ID: 32827461
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Antitumor mechanism of recombinant murine interleukin-12 vaccine.
    Yin X, Yan X, Yang Q, Cao H, Liang H.
    Cancer Biother Radiopharm; 2010 Jun 02; 25(3):263-8. PubMed ID: 20578831
    [Abstract] [Full Text] [Related]

  • 39. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM, Hicks KC, Ozawa Y, Schlom J, Gameiro SR.
    J Immunother Cancer; 2020 Apr 02; 8(1):. PubMed ID: 32303618
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 98.